BlackRock Fund Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

BlackRock Fund Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4K	Buy	9 +3	+50%	+$1.2K	﹤0.01%	4101
2016 Q3	$2K	Buy	6 +1	+20%	+$447	﹤0.01%	4189
2016 Q2	$3K	Sell	5 -53	-91%	-$26.9K	﹤0.01%	4190
2016 Q1	$30K	Sell	58 -5	-8%	-$2.79K	﹤0.01%	3865
2015 Q4	$49K	Buy	63 +3	+5%	+$2.95K	﹤0.01%	3881
2015 Q3	$82K	Buy	60 +5	+9%	+$7.72K	﹤0.01%	3740
2015 Q2	$111K	Buy	+55	New	+$140K	﹤0.01%	3718

Other funds holding HTGM

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

Ironwood Financial Tucson, Arizona $639M AUM 19.03% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

BlackRock Fund Advisors's HTGM Position: Q4 2016 in Review

BlackRock Fund Advisors increased its HTG Molecular Diagnostics, Inc. Common Stock (HTGM) stake by 50% in Q4 2016, buying an estimated $1.2K and bringing the position to 9 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4101.

BlackRock Fund Advisors first reported a position in HTGM in Q2 2015 and has held it in 7 quarters since. The position peaked at $111K in Q2 2015. 13 funds tracked by Wall St. Rank hold HTGM as of Q4 2016.

BlackRock Fund Advisors held 9 shares of HTG Molecular Diagnostics, Inc. Common Stock worth $4K as of Q4 2016.
BlackRock Fund Advisors bought 3 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2016, an estimated $1.2K.
HTG Molecular Diagnostics, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4101 holding.
BlackRock Fund Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $111K in Q2 2015.
13 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.